BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

Post-LOE

betamethasone acetate; betamethasone sodium phosphate

Hikma

ANDAINJECTIONINJECTABLE

Approved

Jan 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE (betamethasone acetate; betamethasone sodium phosphate) by Hikma is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, polymyositis, systemic lupus erythematosus and 16 more indications. First approved in 2023.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…

Indications (19)

dermatomyositis polymyositis

Worked on BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.